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Glycosylated p-hydroxybenzoic acid methyl esters and structur-
ally related phenolphthiocerol glycolipids are important virulence
factors ofMycobacterium tuberculosis. Although both types ofmol-
ecules are thought to be derived from p-hydroxybenzoic acid, the
origin of this putative biosynthetic precursor in mycobacteria
remained to be established. We describe the characterization of a
transposonmutant ofM. tuberculosis deficient in the production of
all forms of p-hydroxybenzoic acid derivatives. The transposon was
found to be inserted in Rv2949c, a gene located in the vicinity of the
polyketide synthase gene pks15/1, involved in the elongation of
p-hydroxybenzoate to phenolphthiocerol in phenolic glycolipid-
producing strains. A recombinant form of the Rv2949c enzyme was
produced in the fast-growing non-pathogenic Mycobacterium
smegmatis and purified to near homogeneity. The recombinant
enzyme catalyzed the removal of the pyruvyl moiety of chorismate
to form p-hydroxybenzoate with an apparent Km value for choris-
mate of 19.7Mand a kcat value of 0.102 s1. Strong inhibition of the
reaction by p-hydroxybenzoate but not by pyruvate was observed.
These results establish Rv2949c as a chorismate pyruvate-lyase
responsible for the direct conversion of chorismate to p-hydroxy-
benzoate and identify Rv2949c as the sole enzymatic source of p-hy-
droxybenzoic acid inM. tuberculosis.
The chorismate pathway, present only in bacteria, fungi, and plants,
provides a wealth of compounds with diverse biological functions,
including aromatic amino acids, folate cofactors, menaquinones,
ubiquinones, pigments, and iron-chelating siderophores. Mycobacte-
rium tuberculosis, the etiological agent of tuberculosis in humans, is no
exception to the rule, and chorismate in this species is the probable
common precursor for the biosynthesis of a series of products (see Fig.
1) that are important both in the physiology and in the pathogenicity of
the bacterium. In addition to folate and aromatic amino acids (pheny-
lalanine, tyrosine, and tryptophan), M. tuberculosis produces salicylic
acid-derived siderophores known asmycobactins (1), isoprenoid quino-
nes of the naphthalene series (menaquinones) (2), and glycosylated
p-hydroxybenzoic acid methyl esters (p-HBAD4s) (3). A few strains of
M. tuberculosis also produce species-specific phenolic glycolipids
(PGL), complex lipids of the cell envelope that share with p-HBADs the
same glycosylated aromatic nucleus. These lipids and their counterparts
found inMycobacterium leprae have been largely associated with path-
ogenicity (4–9). Likewise, preliminary data indicate that p-HBADs,
which are essentially recovered from the secretion products of the
tubercle bacillus,modulate the secretion of pro-inflammatory cytokines
bymurinemacrophages (10) and are required for virulence in immuno-
deficient mice (11).
Because of the important roles played by PGL and p-HBADs in the
pathogenesis of mycobacterial infections, their biosynthesis has stimu-
lated some interest, and, during the last decade, several genes involved
in the synthesis of the lipid core of PGL and in the methylation and
glycosylation of PGL and p-HBADs have been described (3, 12–22).
Most of these genes are clustered on a 70-kilobase region of the chro-
mosome. The synthesis of both p-HBADs and PGL is thought to pro-
ceed from p-hydroxybenzoic acid. Comparison of the chemical struc-
tures of these compounds suggested that, in the biosynthetic route of
p-HBADs, p-hydroxybenzoic acid would be first methylated to p-hy-
droxybenzoic acid methyl ester before being glycosylated and further
methylated. In the case of PGL, p-hydroxybenzoic acid would be elon-
gated by the specialized polyketide synthase Pks15/1 to give p-hydroxy-
phenylalkanoates, which would be in turn converted to phenolphthio-
cerol derivatives in catalytic reactions involving the PpsA-E synthases
(3). The resulting molecules or their diesters, the phenolphthiocerol
dimycocerosates, would be then glycosylated and methylated by the
same enzymes as those involved in the production of p-HBADs to yield
the final PGL molecules (18, 19). The origin of p-hydroxybenzoic acid
(4-HB) in mycobacteria remains, however, to be established.
In Escherichia coli, 4-HB formation from chorismate is the first com-
mitted step in ubiquinone synthesis. The reaction consists of the
removal of the pyruvyl moiety of chorismate and is catalyzed by the
enzyme chorismate pyruvate-lyase (p-hydroxybenzoic acid synthase)
encoded by the ubiC gene (23, 24). The apparent lack of production of
isoprenoid quinones of the benzene series (ubiquinones) inM. tubercu-
losis (2) and the absence of proteins sharing significant sequence simi-
larities with UbiC in the genome of this bacterium made it unclear
whether 4-HB formation in mycobacteria proceeded through the same
route as in E. coli. In the present study, we report the isolation and
characterization of a transposon mutant ofM. tuberculosis deficient in
the production of all forms of 4-HB derivatives and provide evidence
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thatRv2949c, the gene interrupted by the transposon insertion, encodes
a chorismate pyruvate-lyase responsible for the formation of 4-HB from
chorismate.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Conditions—Mt103, the clinical isolate
ofM. tuberculosis used in this study, and the mutant 66C7 were grown
at 37 °C inMiddlebrook 7H9 medium (Difco) supplemented with ADC
(0.2% dextrose, 0.5% bovine serum albumin fraction V, 0.085% NaCl,
0.0003% beef catalase) and 0.05% Tween 80, in minimal Sauton’s
medium (25) or on solid Middlebrook 7H11 medium (Difco) supple-
mented with OADC (0.005% oleic acid, 0.2% dextrose, 0.5% bovine
serum albumin fraction V, 0.085% NaCl, 0.0003% beef catalase). E. coli
XL1-blue, the strain used for cloning experiments, was propagated in
Luria Bertani (LB) broth (pH 7.5) (10 g liter1 Bactotryptone, 5 g liter1
BactoTM yeast extract, 5 g liter1NaCl) (BectonDickinson, Sparks,MD)
at 37 °C. M. smegmatis mc2155 (26) was grown in Middlebrook 7H9
medium (Difco) supplemented with ADC and 0.05% Tween 80 or in LB
broth supplemented with 0.025% tyloxapol at 30 and 37 °C.Where indi-
cated, ampicillin, chloramphenicol, kanamycin, and hygromycin Bwere
added to final concentrations of 100 g ml1, 25 g ml1, 20 g ml1,
and 50 g ml1, respectively.
Identification of the Transposon Insertion Site—The transposon
insertion site in 66C7 was identified by ligation-mediated PCR as
described previously (27). The primers used for amplification were
Salgd (5-tagcttattcctcaaggcacgagc-3), ISada (5-tttgagctctacaccgt-
caagtgcgaagagc-3), IS1 (5-cttctgcagcaacgccaggtccacact-3), and 66C7
(5-ctatctgatcaagagatccg-3). The products were sequenced on a capil-
lary Applied Biosystems ABI 3100 Genetic Analyzer.
Complementation of M. tuberculosis Mutant Strain 66C7 and Over-
expression of Rv2949c in M. smegmatis—Standard PCR strategies with
Vent DNA polymerase (Biolabs) were used to amplify the M. tubercu-
losis H37Rv Rv2949c gene. PCR amplification consisted of predenatur-
ation step (95 °C, 5 min) followed by 35 cycles of denaturation (95 °C, 1
min), annealing (60 °C, 1 min), and primer extension (72 °C, 1.5 min),
and a final extension step at 72 °C for 10 min. The primers, Rv2949c.1
(5-gggcgcccatatgaccgagtgttttctatctgatc-3) and Rv2949c.2 (5-gg-
gaagcttgcgcgccagagtgatggcatttg-3), incorporating NdeI and HindIII
restriction sites (underlined), were designed to amplify the entire
Rv2949c gene for direct cloning into the NdeI and HindIII sites of the
expression vector pVV16 (28). The recombinant Rv2949c protein pro-
duced by the resultant vector, pVV2949c, carried a six-histidine tag at
the carboxyl terminus. 66C7 and M. smegmatis mc2155 were trans-
formed with pVV2949c and transformants were selected for by plating
on 7H11 agar containing kanamycin and hygromycin B. The production
of recombinant Rv2949c protein in 66C7/pVV2949c and mc2155/
pVV2949c transformants was analyzed by immunoblotting with a
mouse monoclonal anti-His antibody (Penta-His antibody, Qiagen) as
previously described (28).
Extraction and Purification of Lipids—For the biochemical analyses
of p-hydroxybenzoate derivatives, the M. tuberculosis strains Mt103,
66C7, and 66C7/pVV2949c were grown in Sauton’s medium as surface
pellicles. p-Hydroxybenzoate derivative production was investigated by
thin-layer chromatography (TLC) analysis of total lipids extracted from
bacterial cells and culture media. Culture filtrates were collected and
filtered through 0.2-m pore-size sterile filters to yield sterile extracel-
lular materials. Exocellular lipids were then extracted by adding 2 vol-
umes of CH3OH and 1 volume of CHCl3 to 0.8 volumes of extracellular
materials to yield a homogeneous single-phase mixture. The mixture
was incubated overnight at room temperature and then partitioned into
twophases by adding 1 volumeofH2O/CHCl3 (1:1, vol:vol). The organic
phase was recovered, washed with 0.9% NaCl, and dried to yield the
subcellular lipid extracts. Total lipids from bacterial cells were extracted
with CHCl3/CH3OH (1:2, vol:vol) for one night followed by two over-
night extractions with CHCl3/CH3OH (2:1, vol:vol). Mycolic acid
methyl esters were prepared from extractable lipids and from delipi-
dated cells by incubation with 15% tetrabutylammonium hydroxide
(Aldrich) overnight at 100 °C followed by methylation with iodometh-
ane (Aldrich) for 4 h at room temperature and extraction with dichlo-
romethane. In some experiments, wholeM. tuberculosis cells grown in
7H9 broth were radiolabeled overnight with [1,2-14C]acetic acid (0.5
Ciml1; specific activity, 113 Cimol1,MP Biomedicals Inc.), a radio-
labeled precursor incorporated in all classes of lipids. Lipids and fatty
acid methyl esters were analyzed on silica gel 60-precoated TLC plates
F254 (Merck) in the solvent systems CHCl3/CH3OH/H2O (90:10:1, vol:
vol:vol) for p-HBADs, petroleum ether (60/80 °C)/ethyl acetate (98:2,
vol:vol, three developments) for dimycocerosates of phthiocerol and
n-hexane(s)/ethyl acetate (95:5, vol:vol, three developments) for fatty
acid and mycolic acid methyl esters. An -naphthol spray (1% -naph-
thol in ethanol) and a cupric sulfate spray (10% CuSO4 in a 8% phos-
phoric acid solution) were used to detect carbohydrate-containing lip-
ids and all organic compounds, respectively. Radiolabeled lipids and
fatty acids were visualized by exposure of TLC to Kodak BIOMAXMR
films at70 °C.Unmethylated p-HBAD-I standardwas kindly provided
by Drs. A. Liav and V. Vissa from Colorado State University (Fort Col-
lins, CO). Cell-associated and exocellular mycobactins were extracted
in the presence of ferric chloride as described previously (29) and ana-
lyzed by TLC using the solvent system ethanol/petroleum ether (60/
80 °C)/ethyl acetate (1:4:6, vol:vol:vol).
p-HBADs were purified from the culture filtrate of the comple-
mented strain 66C7/pVV2949c by preparative TLC using CHCl3/
CH3OH/H2O (90:10:1, vol:vol:vol) as the eluent. The products of inter-
est were scraped off and eluted from the silica with CHCl3/CH3OH (2:1,
vol:vol).
Matrix-assisted Laser Desorption Ionization Time-of-Flight (MALDI-
TOF) Mass Spectrometry—MALDI mass spectrometry was performed
using a voyager DE-STR MALDI-TOF instrument (PerSeptive Biosys-
tems) equipped with a pulse nitrogen laser emitting at 337 nm. Samples
were analyzed in the Reflector mode using an extraction delay time set
at 100 ns and an accelerating voltage operating in positive ion mode of
20 kV. The mass spectra were mass-assigned by external calibration.
Samples (1 l of a 1 mg ml1 solution in CHCl3) were directly applied
onto the sample plate. Thematrix solution (0.5l of 2,5-dihydroxyben-
zoic acid at 10mgml1 in CHCl3/CH3OH (1:1, vol:vol)) was added. The
samples were then allowed to crystallize at room temperature.
Chemical Analysis—4-HB derivatives were methanolized using
CH3OH/HCl prepared by the acetyl chloride reaction on methanol in
anhydrous conditions. Samples were dissolved in 500 l of CH3OH/
HCl (1N) and incubated overnight at 80 °C under nitrogen atmosphere.
The solvent was evaporated under nitrogen and then co-evaporated
three times with anhydrous CH3OH.
For trimethylsilyl derivatization, samples were dissolved in 200 l of
anhydrous pyridine, followed by the addition of 100 l of hexamethyl-
disilazane and 50 l of trimethylchlorosilane. The reaction was incu-
bated at room temperature for 30 min. The mixture was dried under
nitrogen, and the trimethylsilyl derivatives were solubilized in either
petroleum ether, for gas chromatography (GC) and GC-mass spec-
trometry (GC/MS) or in CHCl3 for MALDI-mass spectrometry.
GC and GC/MS Analysis—GC analyses were performed using a
Girdel series 30 instrument equipped with an OV1 capillary column
p-Hydroxybenzoate Synthesis inMycobacterium tuberculosis
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(0.30 mm  25 m) using helium gas (0.7 bar) with a flame ionization
detector at 310 °C. The temperature program was from 60 to 310 °C, at
5 °C min1. GC/MS analyses were performed on a Hewlett-Packard
5889 Xmass spectrometer (electron energy, 70 eV) working in electron
impact (EI) mode, coupled with a Hewlett-Packard 5890 series II gas
chromatograph fitted with a similar OV1 column (0.30 mm 12 m).
Production and Purification of Recombinant Enzymes fromE. coli and
M. smegmatis—TheM. tuberculosisH37RvRv2949c genewas amplified
by PCR from genomic DNA using the pair of primers Rv2949c.tb1 (5-
ggccgcccatatgaccgagtgttttctatctgatc-3) and Rv2949c.tb2 (5-gccggatc-
ctagcgcgccagagtgatggc-3). Primers were designed to create NdeI and
BamHI restriction sites (underlined) enabling direct cloning of the PCR
product into the corresponding restriction sites of the expression vector
pET14b (Novagen). The resulting expression plasmid, pETRv2949cwas
used to transform E. coli BL21(DE3)pLysS cells. Recombinant bacteria
were grown overnight in LB-chloramphenicol-ampicillin broth at 37 °C
and then transferred to 200ml of the samemedium at 30 °C.WhenA600
reached 0.7–0.8, isopropyl--D-thiogalactopyranoside was added to a
final concentration of 0.05 mM, and incubation was continued for an
additional 3 h at 30 °C. Production of the recombinant protein was
confirmed by SDS-PAGE with Coomassie Brilliant Blue 250R staining
and by Western blot using a mouse monoclonal anti-His antibody
(Penta-His antibody, Qiagen).
E. coli cells producing recombinant enzyme were washed and resus-
pended in buffer A (50 mM Tris-HCl, pH 7.5, 10 mM -mercaptoetha-
nol). Cells were disrupted by probe sonication on ice (4 cycles of 30 s on
and 90 s off), and the resulting sonicate was centrifuged at 1,200 g for
20 min. The pellet was discarded, and the supernatant containing the
soluble M. tuberculosis His-tagged protein was loaded onto a cobalt-
based immobilized metal affinity BD TALON™ Spin Column (Clon-
tech). Unbound proteins were removed bywashing the resinwith buffer
A containing 10 mM imidazole, and His-tagged protein bound to the
resin was then gradually eluted with buffer A containing increasing
concentrations of imidazole (50, 150, 300, 500, and 1,000 mM). The
recombinant Rv2949c protein was detected by SDS-PAGE in the frac-
tions eluted with 150, 300, 500, and 1,000 mM imidazole. Fractions that
were estimated to be at least 90% pure by Coomassie Blue staining were
pooled, desalted using a PD-10 column (Amersham Pharmacia Bio-
tech), concentrated in an Amicon Ultra-15 (10,000 MWCO) (Milli-
pore), and used for further characterization.
mc2155/pVV2949c, theM. smegmatis strain overexpressingRv2949c,
was obtained upon transformation of mc2155 with the expression vec-
FIGURE 1.Chorismate-utilizing pathways inM. tuberculosis. The trisaccharide substituent found in p-HBAD-II, consists of 2,3,4-tri-O-methyl--L-Fucp-(133)--L-Rhap-(133)-2-O-
methyl--L-Rhap. The monosaccharide substituent found in p-HBAD-I consists of 2-O-methyl--L-Rhap.
p-Hydroxybenzoate Synthesis inMycobacterium tuberculosis
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tor pVV2949c. Cells were grown in LB-kanamycin-tyloxapol broth at
30 °C and collected by centrifugation, and the production of recombi-
nant Rv2949c protein was analyzed by Western blotting as described
above. For the purification of recombinant His-tagged Rv2949c protein,
mc2155/pVV2949c cells (1 g of wet weight) were washed and resus-
pended in 2 ml of buffer A before probe sonication for 9 min at 4 °C in
the form of nine 60-s pulses with 90-s cooling intervals between pulses.
The unbroken cells and bacterial debris were removed by centrifugation
of the sonicate at 700 g for 10 min, and the recombinant His-tagged
Rv2949c protein was purified from the supernatant of this centrifuga-
tion using a BD TALON™ Spin Column as described for the recombi-
nant protein produced in E. coli. Recombinant Rv2949c protein was
detected in the fractions eluted with 150, 300, 500, and 1,000 mM imid-
azole. These fractions were pooled, desalted, and concentrated as
described above.
Chorismate Pyruvate-lyase Assay—Chorismate pyruvate-lyase activ-
ity wasmonitored using a coupled photometric assay protocol similar to
that of Siebert et al. (30). The release of pyruvate from chorismate,
which occurs in the course of the reaction, was monitored by following
NADH oxidation in a second reaction that was not rate-limiting.
Decrease in absorbance was measured over time at 340 nm in a Beck-
man Coulter DU-800 spectrophotometer. The standard assay was per-
formed at 37 °C and contained in a final volume of 1 ml: chorismate
(25–500 M) (Sigma), 50 mM Tris-HCl (pH 7.5), 200 M NADH, 5.5
units of lactate dehydrogenase (Sigma), and 0.472M (10g) of purified
recombinant Rv2949c enzyme. For the determination of kinetic param-
eters, incubations were carried out for 2 min to measure accurately
initial reaction velocities and to minimize product-inhibition effects.
In some experiments (to analyze pH dependence and inhibition by
pyruvate), NADH and lactate dehydrogenase were omitted from the
reaction mixture, and the reactions were stopped at different time
points by adding 600 l of sodium acetate (0.75 M, pH 4). The p-hy-
droxybenzoate formed in the reaction was directly detected and quan-
titated by HPLC. 100 l of each reaction mixture was applied to an
HPLC system (Shimadzu) equipped with a reverse phase Hypersil ODS
column (250  4.6 mm, particle size 5 m) (Thermo). Elution was
isocratic at 1 ml min1 using water/acetonitrile/acetic acid (80:10:5,
vol:vol:vol) as the solvent system. Analytes were detected at 240 nm.
RESULTS
Isolation of a Rv2949cMutant ofM. tuberculosisMt103 fromaTrans-
poson Mutant Library—Mutants of M. tuberculosis Mt103 carrying
transposon insertions in a region of the chromosome associated with
the synthesis of PGL and structurally related glycosylated p-HBADs
were recently isolated (10). One of these mutants, 66C7, which carried
an insertion 237 base pairs downstream from the predicted start codon
of the previously uncharacterized geneRv2949c, was selected for further
studies.
Rv2949c is located upstream from the pks15/1 genes (Rv2947c/
Rv2946c) in the genome ofM. tuberculosisH37Rv and has orthologs in
other PGL-producing species of mycobacteria such as M. leprae,
M. bovis, andM.marinum. In fact, in the latter species, two orthologs of
Rv2949c (sharing 75 and 67% similarity with Rv2949c at the amino acid
level) were identified. At the amino acid level, Rv2949c (199 amino
acids) shows some sequence similarities with putative chorismate pyru-
vate-lyases (p-hydroxybenzoic acid synthases) from Archaea (48% sim-
ilarity on a 155-amino-acid overlap with the protein of Archaeoglobus
fulgidus, 44% similarity on a 174-amino-acid overlap with the protein of
Methanococcus jannaschii), and Streptomyces capreolus (44% similarity
on a 180-amino-acid overlap) but no significant similarities with the
chorismate pyruvate-lyase of E. coli, UbiC. As the location of Rv2949c
on the chromosome suggested a possible involvement of this gene in the
metabolism of p-HBADs and PGL, we sought to determine whether it
participated in the synthesis of the aromatic nucleus of these important
biological molecules.
Biochemical Phenotype of the Rv2949c Mutant—Important differ-
ences were found between the p-HBAD content of Mt103 and 66C7
(Fig. 2). Although wild-type Mt103 released into the culture medium
the mono- and triglycosylated forms of p-hydroxybenzoic acid methyl
esters, p-HBAD-I and p-HBAD-II (Fig. 1), there was no evidence for the
production of either of these two glycosylated 4-HB derivatives in the
culture medium or in bacterial cells of 66C7 (Fig. 2). 66C7 also clearly
lacked two other glycoconjugates. One of these, UM-p-HBAD-I, was
identified by co-migration with an authentic standard as being rham-
nosyl--p-hydroxybenzoic acid methyl ester, a truncated form of
p-HBAD-I carrying an unmethylated rhamnosyl residue. The second
compound (a) was purified and first analyzed by MALDI-TOF mass
spectrometry. Themass spectrum showed a pseudomolecular ion (M
Na) peak at m/z 641 Da (Fig. 3B). This mass value is 28 mass units
lower than that observed for p-HBAD-II (Fig. 3A), suggesting that com-
pound a corresponds to an undermethylated form of p-HBAD-II. To
determine the number of free hydroxyl groups in compound a, the
substance was trimethylsilylated and reanalyzed by MALDI-TOF mass
spectrometry. Themass spectrumof the trimethylsilylated compound a
showed pseudomolecular ion peaks atm/z 713, 785, 857, 929, and 1,001
Da (Fig. 3C). The peak atm/z 1,001 Da corresponds to the pertrimeth-
ylsilylated compound a bearing five trimethylsilyl groups; the remaining
pseudomolecular ion peaks correspond to undertrimethylsilylated
forms of compound a that contain either one, two, three, or four tri-
methylsilyl groups. These data indicated that the native compound a
contains five free hydroxyl groups. Thus, compared with p-HBAD-II,
and in agreement with the 28 mass units default, compound a corre-
sponds to a substance lacking two O-methyl substituents on the sugar
moiety. Acid methanolysis of the purified compound a, followed by GC
FIGURE 2. Thin-layer chromatography analysis of lipids extracted from the culture
supernatants of M. tuberculosis strains Mt103, 66C7, and 66C7/pVV2949c. Equal
volumes of lipid extracts prepared from culture filtrates ofM. tuberculosisMt103, 66C7,
and 66C7/pVV2949c (66C7compl) were applied to a TLC plate and developed in CHCl3/
CH3OH/H2O (90:10:1). The plate was revealed with -naphthol. 1 g of unmethylated
p-HBAD-I (UM-p-HBAD-I) was used as the migration standard.
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and GC-MS analyses of the trimethylsilyl derivatives of the methanoly-
sate and of various standards, identified 2-O-methylfucose, 2-O-meth-
ylrhamnose, and rhamnose as the sugar constituents of compound a
(data not shown). The non-carbohydrate moiety of the compound was
identified by GC-MS as p-hydroxybenzoic acid methyl ester (data not
shown). We thus concluded that compound a corresponds to the tri-
glycosylated form of p-HBAD inwhich the trisaccharide part consists of
2-O-methyl--L-Fucp-(133)--L-Rhap-(133)-2-O-methyl--L-Rhap.
The 133 -linkages between the three sugar units were assumed by
analogy with the structure of p-HBAD-II (3). Compound a is either an
intermediate product in the biosynthetic pathway leading to
p-HBAD-II from p-HBAD-I or a degradation product of p-HBAD-II.
Complementation of 66C7 with a wild-type copy of Rv2949c placed
under control of the hsp60 promoter and carried on a multicopy plas-
mid clearly restored the production of all glycoconjugates in themutant,
including that of p-HBAD-I and p-HBAD-II (Fig. 2). Their synthesis,
especially that of unmethylated p-HBAD-I (Fig. 2), appeared to be
slightly increased in 66C7/pVV2949c as compared with Mt103, most
likely because of the strong expression of Rv2949c in the complemented
strain. Interestingly, only a tiny amount, if any, of free 4-HB could be
detected by TLC in the different lipid batches prepared from the wild-
type and complemented strains (data not shown) suggesting that this
product is immediately metabolized upon synthesis. The impact of dis-
rupting Rv2949c on PGL production could not be tested in the context
of this study as the clinical isolate M. tuberculosis Mt103 is naturally
devoid of these molecules (3).
TLC analyses of non radiolabeled and [1,2-14C]acetate-derived lipids
fromMt103 and 66C7 revealed no other quantitative or qualitative dif-
ference in the cell envelope composition or in the secreted products of
the two strains (including their phthiocerol dimycocerosate content)
(data not shown). Likewise, the same types and amounts of mycolates
esterifying arabinogalactan and outer membrane glycolipids (predomi-
nantly trehalose mono- and dimycolates) were recovered from Mt103
and 66C7 (data not shown).
Finally, as chorismate pyruvate-lyase (involved in the formation of
4-HB from chorismate) and isochorismate pyruvate-lyase (responsible
for the formation of salicylic acid from isochorismate) catalyze similar
reactions, we verified whether the disruption of Rv2949c in 66C7 had
FIGURE3.MALDI-TOFmass spectraofp-HBAD-II
(A), native (B), and trimethylsilylated (C) com-
pound a. Samples (1l of a 1mgml1 solution in
CHCl3)weredirectly appliedonto the sampleplate
and then allowed to crystallize at room tempera-
ture. Sampleswere analyzed in theReflectormode
using an extraction delay time set at 100 ns and an
accelerating voltage operating in positive ion
mode of 20 kV. Thematrix solution used consisted
of 2,5-dihydroxybenzoic acid (10 mg ml1 in
CHCl3/CH3OH (1:1, vol:vol)).
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any effect on the production of salicylic acid-derived mycobactins (Fig.
1). This analysis was further prompted by the fact that, to date, the genes
involved in the formation of the salicylate moiety in mycobactin sid-
erophores have not been clearly defined (1, 31). To conduct this analysis,
wild-typeMt103 and 66C7were grown in low iron Sauton’smedium (in
which ferric ammonium citrate was omitted) to stimulate siderophore
production. Both the cell-associated and the secreted forms of myco-
bactin were extracted and analyzed by TLC (Fig. 4). No difference was
found between the two strains indicating that Rv2949c is not required
for mycobactin formation.
66C7 grew at the same rate as its parent strain Mt103 in 7H9 and in
Sauton’s medium at 37 °C (data not shown). In contrast, compared with
the other strains, the growth of the complemented mutant, 66C7/
pVV2949c, in Sauton’s medium was delayed by 5 weeks suggesting
that overexpression of Rv2949c had some toxic effects on the cells. This
observation was not unexpected with regard to the well known antibac-
terial and antifungal activities of 4-HB esters (32). Together, these
results suggest that Rv2949c specifically encodes the enzyme responsi-
ble for the production of the aromatic nucleus of all p-HBADs and that
it is the sole enzymatic source of 4-HB inM. tuberculosis.
Production of Recombinant Forms of Rv2949c in M. smegmatis and
E. coli—To characterize the function of Rv2949c, recombinant forms of
this protein were produced and purified. Because some studies aimed at
analyzing the structure, post-translational modifications, and immuno-
genicity of mycobacterial proteins have highlighted the superiority of
recombinant proteins purified from mycobacterial hosts compared
with E. coli-derived products (33–36), both an E. coli and a M. smeg-
matis expression system were used and compared.
For the production of Rv2949c inM. smegmatis, the expression plas-
mid for complementation experiments described above was used.
M. smegmatis mc2155 was transformed with pVV2949c or with the
empty pVV16 vector and recombinant clones were selected on LB-
kanamycin plates at 30 °C. mc2155/pVV2949c transformants grew very
poorly in LB-tyloxapol broth at 37 °C but grew at about the same rate as
mc2155/pVV16 at 30 °C (data not shown). Production of recombinant
carboxyl-terminal hexahistidine-tagged Rv2949c protein of the
expected size (22.6 kDa) was confirmed by Western blot (data not
shown); however, the production of the protein was found to be quite
unstable as it was lost after more than two passages of the recombinant
clones in liquid broth. Interestingly, when 7H9-ADC-Tween 80 broth
was used instead of LB-Tween 80, mc2155/pVV2949c transformants
were able to grow similarly to the control strain at 30 and 37 °C, but the
production of recombinant protein in this medium was much less than
in LB broth (data not shown). Therefore, consistent with the observa-
tions made on 66C7/pVV2949c, overexpression of Rv2949c had some
toxic effects on M. smegmatis, which could be partially reversed by
growing the cells at 30 °C. mc2155/pVV2949c grown in LB broth at
30 °C was, thus, used to produce Rv2949c, and the recombinant protein
was purified to near homogeneity from these cells as described under
”Experimental Procedures“ (Fig. 5, lane 1).
Recombinant amino-terminal hexahistidine-tagged Rv2949c protein
was also produced in E. coli using the pET14b expression system.
Although more than 80% of the protein produced was in the insoluble
fraction (under the form of inclusion bodies) (data not shown), suffi-
cient amounts of the protein were recovered in the soluble extract to
allow the purification of native recombinant Rv2949c from E. coli
BL21(DE3)pLysS (Fig. 5, lane 2). Both forms of recombinant Rv2949c
were used in enzymatic assays.
Characterization of Rv2949c as a Chorismate Pyruvate-lyase—Cho-
rismate pyruvate-lyase produces 4-HB by releasing pyruvate from cho-
rismate. To analyze and compare the catalytic activities of the recom-
binant proteins produced in M. smegmatis and in E. coli, an activity
assay based on that developed for the UbiC protein of E. coli was used
(30). The release of pyruvate from chorismate was monitored over time
FIGURE 4. Mycobactin production in Mt103 and 66C7. Mycobactins were extracted
from bacteria grown in low-iron Sauton’s medium as described under ”Experimental
Procedures“. Theywere then applied to a TLC plate and developed in the solvent system
ethanol/petroleum ether (60°/80 °C)/ethyl acetate (1:4:6). Upon fixation of iron from fer-
ric chloride during the extraction process, mycobactins develop a rusty color allowing
their detection on the plate. Only the cell-associated mycobactins are shown.
FIGURE 5. Purification of recombinant forms of Rv2949c from M. smegmatis and
E. coliBL21(DE3)pLysS. 1g of purified recombinant proteins fromM. smegmatis (lane
1) and from E. coli BL21DE3pLysS (lane 2) were submitted to SDS-PAGE and visualized by
staining with Coomassie Brilliant Blue 250R.MWM, molecular weight marker.
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using a coupled photometric assay that was not rate-limiting. 4-HB
formation was also directly detected by HPLC.
No spontaneous (i.e. non-enzymatic) degradation of chorismate to
4-HB occurred under the conditions used in the assay over a 30-min
incubation (data not shown). However, when either form of purified
recombinant Rv2949c (amino-terminal or carboxyl-terminal His-
tagged) was added to the reaction mixture, pyruvate was released from
chorismate to form 4-HB in a time-dependent fashion. The substrate
saturation curves were hyperbolic for both enzymes indicating that they
followed Michaelis Menten’s kinetics. Non-linear regression analysis
was conducted on the curves, and steady-state kinetic parameters were
calculated (Fig. 6). The apparent Km values for chorismate were deter-
mined as 19.7 M for the recombinant Rv2949c produced in M. smeg-
matis (Fig. 6A) and as 39.6 M for the enzyme produced in E. coli (Fig.
6B). kcat values were determined as 0.102 and 0.215 s1, respectively.
These kcat values are about 10-fold lower than those reported for the
E. coliUbiC protein (1.5 s1) (37). Comparable kinetic parameters were
obtained when pyruvate release was monitored using the coupled pho-
tometric assay or when 4-HB formation was directly quantified by
HPLC (data not shown).
The addition of 10 mM MgCl2 to the reaction buffer had neither a
stimulatory nor an inhibitory effect on the activity of Rv2949c produced
inM. smegmatis suggesting that this enzyme, like the E. coli UbiC pro-
tein, has no requirement for Mg2 (data not shown). pH dependence
was also studied using buffers containing Tris-HCl and glycine-NaOH.
The enzyme was found to be active over a range of pH between 6.8 and
10 with an optimum pH at 7.5 (data not shown). As reported for the
UbiC enzyme, a strong product inhibition was observed in the presence
of 4-HB. Using a chorismate concentration close to the apparent Km
value, i.e. 25 M, the addition of 100 M 4-HB to the reaction mixture
reduced pyruvate formation by 86% after 10min of incubation. Pyruvate
formation after the same incubation time was reduced by 65 and 46%
when chorismate concentration was raised to 250 and 500 M, respec-
tively. This partial reversion of inhibition in the presence of excess cho-
rismate is suggestive of a competitive inhibition. The initial rate inhibi-
tion because of 4-HBwasmeasured, and the inhibition constant (Ki) for
this product was determined to be 6 M, close to the Ki value for 4-HB
of UbiC (2.1 M) (37). In contrast, using a chorismate concentration of
100 M, pyruvate did not show any inhibitory effect at concentrations
up to 1mM (data not shown). Finally, in the presence of 10% glycerol, the
purified recombinant enzymes could be stored at 20 °C for at least 3
weeks without significant loss of activity.
DISCUSSION
This study establishes that Rv2949c encodes a chorismate pyruvate-
lyase (4-HB synthase) responsible for the production of 4-HB from cho-
rismate and that it is the sole enzymatic source of this product in
M. tuberculosis. Interestingly, Rv2949c shares some sequence similari-
ties with putative chorismate pyruvate-lyases from Archaea and Strep-
tomyces capreolus but shows no significant similarity with the choris-
mate pyruvate-lyase of E. coli, UbiC. Although the three-dimensional
structure of Rv2949c remains to be determined, and comparedwith that
of other chorismate-utilizing enzymes, this finding tends to support the
earlier observation that these enzymes are examples of convergent evo-
lution toward similar reaction capabilities rather than enzymes arising
from divergent evolution (31).
From our complementation experiment, it seems that inM. tubercu-
losisMt103, 4-HB is immediatelymetabolized into p-HBADs. Although
one cannot totally exclude from our analyses that 4-HB is the precursor
of multiple end products, it seems likely that p-HBADs (and PGL in
phenolglycolipid-producing strains) are the major metabolic end prod-
ucts derived from 4-HB produced by tubercle bacilli. M. tuberculosis
strains are apparently devoid of ubiquinones (2), and, to our knowledge,
no other complex compound sharing the same aromatic nucleus as
p-HBADs has yet been described in this species. It is, therefore, puzzling
to observe that all M. tuberculosis strains have retained the ability to
produce such complex molecules. The fact that the 66C7 mutant did
not exhibit any growth defect when cultured under axenic conditions
argues against amajor role of 4-HB derivatives in the in vitro physiology
FIGURE 6. Double reciprocal plots of initial velocity versus chorismate concentra-
tion. Purified recombinant forms of Rv2949c produced inM. smegmatis (A) and E. coli (B)
were used. Incubations were carried out for 2 min to measure accurately initial reaction
velocities and to minimize product-inhibition effects. The chorismate concentration
ranged from 25 to 500 M.
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of the tubercle bacillus. The structure of phenolic glycolipids and the
observation that some of the PGL species produced by M. marinum
were O-acylated with mycoloyl residues led Gastambide-Odier (38) to
propose that these molecules acted as carriers of key constituents of the
cell envelope. Accordingly, a thorough analysis of the lipid and mycolic
acid content of 66C7 was undertaken in the present study to investigate
this possibility, and, as no qualitative or quantitative difference was
found between the mutant and the wild-type strain, we conclude that
p-HBADs are unlikely to be carriers of key envelope constituents.
A more likely explanation for the conservation of p-HBADs and the
occurrence of PGL in someM. tuberculosis strains is related to their role
in pathogenesis. Remarkably, glycosylated phenolphthiocerol diesters
are only found in a few Mycobacterium species, namely M. ulcerans,
M.marinum,M. tuberculosis,M. bovis,M. leprae,M. kansasii,M. gastri,
M.microti, andM. hemophilum (39).With the exception ofM. gastri, all
of these species are pathogenic for humans. Although PGL are well
known virulence factors of M. leprae playing pleiotropic roles in the
course of leprosy (5–8), evidence for the contribution of 4-HB deriva-
tives to the pathogenesis of tuberculosis has been provided only
recently. It was shown that the low innate immunogenicity and hyper-
virulence of a Beijing isolate ofM. tuberculosis was associated with the
presence of PGL in this strain (9). Moreover, a Rv2958c mutant of M.
tuberculosisH37Rv, likely to be affected in the production of the di- and
triglycosylated forms of p-HBADs (18), exhibited a decreased virulence
in immunodeficient mice (11). Finally, our data indicate that a Rv2958c
mutant constructed inM. tuberculosisMt103 inducesmouse bonemar-
row-derived macrophages to secrete more proinflammatory cytokines
than the wild-type strain (10). Thus, it is clear that both p-HBADs and
PGL play important roles in the modulation of the host immune
response and that the glycosylated aromatic nucleus of these molecules
is directly involved in some of their biological activities. The availability
of 66C7, aM. tuberculosismutant devoid of all forms of p-HBADs, now
provides a unique opportunity to measure the contribution of these
molecules to immunopathogenesis.
Acknowledgments—We thank C. Chaput and I. Boneca for their assistance
with HPLC, H. Munier-Lehman for helpful discussion, and K. Davenport and
K. Mikusova´ for critical reading of the manuscript.
REFERENCES
1. De Voss, J. J., Rutter, K., Schroeder, B. G., and Barry, C. E., III (1999) J. Bacteriol. 181,
4443–4451
2. Collins, M. D., and Jones, D. (1981)Microbiol. Rev. 45, 316–354
3. Constant, P., Pe´rez, E.,Malaga,W., Lane´elle,M.-A., Saurel, O., Daffe´,M., andGuilhot,
C. (2002) J. Biol. Chem. 277, 38148–38158
4. Brennan, P. J. (1988) inMicrobial Lipids (Ratledge, C., andWilkinson, S. G., eds) Vol.
1, pp. 203–298, Academic Press Ltd., London
5. Chan, J., Fujiwara, T., Brennan, P. J., McNeil, M., Turco, S. J., Sibille, J.-C., Snapper,
M., Aisen, P., and Bloom, B. R. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2453–2457
6. Puzo, G. (1990) Critic. Rev. Microbiol. 17, 305–327
7. Ng, V., Zanazzi, G., Timpl, R., Talts, J. F., Salzer, J. L., Brennan, P. J., and Rambukkana,
A. (2000) Cell 103, 511–524
8. Schlesinger, L. S., and Horwitz, M. A. (1991) J. Exp. Med. 174, 1031–1038
9. Reed, M. B., Domenech, P., Manca, C., Su, H., Barczak, A. K., Kreiswirth, B. N.,
Kaplan, G., and Barry, C. E., III (2004) Nature 431, 84–87
10. Griffin, R., StadthagenGomez, G., Young, D., Coade, S., Bottova´, I., Nigou, J., Brando,
T., Puzo, G., Gicquel, B., Lowrie, D., Jackson, M., and Tascon, R. E. (2005) Keystone
Symposium, British Columbia, April 2–7, 2005, Bill and Melinda Gates Foundation,
Whistler, British Columbia, Canada
11. Hisert, K. B., Kirksey, M. A., Gomez, J. E., Sousa, A. O., Cox, J. S., Jacobs Jr., W. R.,
Nathan, C. F., and McKinney, J. D. (2004) Infect. Immun. 72, 5315–5321
12. Azad, A. K., Sirakova´, T. D., Rogers, L. M., and Kolattukudy, P. E. (1996) Proc. Natl.
Acad. Sci. U. S. A. 93, 4787–4792
13. Azad, A. K., Sirakova´, T. D., Fernandes, N. D., and Kolattukudy, P. E. (1997) J. Biol.
Chem. 272, 16741–16745
14. Fitzmaurice, A. M., and Kolattukudy, P. E. (1998) J. Biol. Chem. 273, 8033–8039
15. Camacho, L. R., Ensergueix, D., Pe´rez, E., Gicquel, B., and Guilhot, C. (1999) Mol.
Microbiol. 34, 257–267
16. Cox, J. S., Chen, B., McNeil, M., and Jacobs Jr., W. R. (1999) Nature 402, 79–83
17. Camacho, L. R., Constant, P., Raynaud, C., Lane´elle, M.-A., Triccas, J. A., Gicquel, B.,
Daffe´, M., and Guilhot, C. (2001) J. Biol. Chem. 276, 19845–19854
18. Pe´rez, E., Constant, P., Lemassu, A., Laval, F., Daffe´, M., and Guilhot, C. (2004) J. Biol.
Chem. 279, 42574–42583
19. Pe´rez, E., Constant, P., Laval, F., Lemassu, A., Lane´elle, M.-A., Daffe´, M., and Guilhot,
C. (2004) J. Biol. Chem. 279, 42584–42592
20. Onwueme, K. C., Ferreras, J. A., Buglino, J., Lima, C. D., and Quadri, L. E. N. (2004)
Proc. Natl. Acad. Sci. U. S. A. 101, 4608–4613
21. Trivedi, O. A., Arora, P., Sridharan, V., Tickoo, R., Mohanty, D., and Gokhale, R. S.
(2004) Nature 428, 441–445
22. Trivedi, O. A., Arora, P., Vats, A., Ansari, M. Z., Tickoo, R., Sridharan, V., Mohanty,
D., and Gokhale, R. S. (2005)Mol. Cell 17, 631–643
23. Siebert, M., Bechthold, A., Melzer, M., May, U., Berger, U., Schro¨der, G., Schro¨der, J.,
Severin, K., and Heide, L. (1992) FEBS Lett. 307, 347–350
24. Nichols, B. P., and Green, J. M. (1992) J. Bacteriol. 174, 5309–5316
25. Sauton, M. B. (1912) C. R. Acad. Sci. 155, 860–861
26. Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., and Jacobs, W. R. (1990) Mol.
Microbiol. 4, 1911–1919
27. Prod’hom, G., Lagier, B., Pelicic, V., Hance, A. J., Gicquel, B., and Guilhot, C. (1998)
FEMS Microbiol. Lett. 158, 75–81
28. Kordulakova´, J., Gilleron, M., Mikusova´, K., Puzo, G., Brennan, P. J., Gicquel, B., and
Jackson, M. (2002) J. Biol. Chem. 277, 31335–31344
29. De Voss, J. J., Rutter, K., Schroeder, B. G., Su, H., Zhu, Y., and Barry III, C. E. (2000)
Proc. Natl. Acad. Sci. U. S. A. 97, 1252–1257
30. Siebert, M., Severin, K., and Heide, L. (1994)Microbiology 140, 897–904
31. Dosselaere, F., and Vanderleyden, J. (2001) Crit. Rev. Microbiol. 27, 75–131
32. Soni, M. G., Taylor, S. L., Greenberg, N. A., and Burdock, G. A. (2002) Food Chem.
Tox. 40, 1335–1373
33. Garbe, T., Harris, D., Vordermeier, M., Lathigra, R., Ivanyi, J., and Young, D. (1993)
Infect. Immun. 61, 260–267
34. Triccas, J. A., Roche, P. W., Winter, N., Feng, C. G., Butlin, C. R., and Britton, W. J.
(1996) Infect. Immun. 64, 5171–5177
35. Roche, P. W., Winter, N., Triccas, J. A., Feng, C., and Britton, W. J. (1996) Clin. Exp.
Immunol. 103, 226–232
36. Daugelat, S., Kowall, J., Mattow, J., Bumann, D., Winter, R., Hurwitz, R., and Kauf-
mann, S. H. (2003)Microbes Infect. 5, 1082–1095
37. Holden, M. J., Mayhew, M. P., Gallagher, D. T., and Vilker, V. L. (2002) Biochim.
Biophys. Acta 1594, 160–167
38. Gastambide-Odier, M. (1973) Eur. J. Biochem. 33, 81–86
39. Daffe´, M., and Draper, P. (1998) Adv. Microb. Physiol. 39, 131–203
p-Hydroxybenzoate Synthesis inMycobacterium tuberculosis
40706 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 280•NUMBER 49•DECEMBER 9, 2005
 at U
N
IV
 O
F N
O
TTIN
G
H
A
M
 on D
ecem
ber 12, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Nathalie Barilone, Brigitte Gicquel, Mamadou Daffé and Mary Jackson
Gustavo Stadthagen, Jana Korduláková, Ruth Griffin, Patricia Constant, Iveta Bottová,
Mycobacterium tuberculosis-Hydroxybenzoic Acid Synthesis in p
doi: 10.1074/jbc.M508332200 originally published online October 6, 2005
2005, 280:40699-40706.J. Biol. Chem. 
  
 10.1074/jbc.M508332200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/280/49/40699.full.html#ref-list-1
This article cites 37 references, 18 of which can be accessed free at
 at U
N
IV
 O
F N
O
TTIN
G
H
A
M
 on D
ecem
ber 12, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
